Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab

IMPORTANCE: The addition of consolidative durvalumab to chemoradiation has improved disease control and survival in locally advanced non–small cell lung cancer (NSCLC). However, there remains a need to identify biomarkers for response to this therapy to allow for risk adaptation and personalization....

Descripción completa

Detalles Bibliográficos
Autores principales: Lebow, Emily S., Shepherd, Annemarie, Eichholz, Jordan E., Offin, Michael, Gelblum, Daphna Y., Wu, Abraham J., Simone, Charles B., Schoenfeld, Adam J., Jones, David R., Rimner, Andreas, Chaft, Jamie E., Riaz, Nadeem, Gomez, Daniel R., Shaverdian, Narek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856786/
https://www.ncbi.nlm.nih.gov/pubmed/36602799
http://dx.doi.org/10.1001/jamanetworkopen.2022.49591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856786/
https://www.ncbi.nlm.nih.gov/pubmed/36602799
http://dx.doi.org/10.1001/jamanetworkopen.2022.49591

Ejemplares similares